These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 34155799)

  • 1. Current management of NAFLD/NASH.
    Cardoso AC; de Figueiredo-Mendes C; A Villela-Nogueira C
    Liver Int; 2021 Jun; 41 Suppl 1():89-94. PubMed ID: 34155799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments.
    Roeb E; Geier A
    Z Gastroenterol; 2019 Apr; 57(4):508-517. PubMed ID: 30965381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is Nonalcoholic Fatty Liver Disease Indeed the Hepatic Manifestation of Metabolic Syndrome?
    Katsiki N; Perez-Martinez P; Anagnostis P; Mikhailidis DP; Karagiannis A
    Curr Vasc Pharmacol; 2018; 16(3):219-227. PubMed ID: 28669328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions.
    Gerges SH; Wahdan SA; Elsherbiny DA; El-Demerdash E
    Life Sci; 2021 Apr; 271():119220. PubMed ID: 33592199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].
    Kim SK; Kim KI; Kim SR
    Yakugaku Zasshi; 2019; 139(9):1147-1153. PubMed ID: 31474630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Advances in diagnosis and treatment of nonalcoholic fatty liver disease].
    Zhu C; Zhou D; Fan J
    Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):81-4. PubMed ID: 26983471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-alcoholic fatty liver disease - how to effectively fight the nowadays most common liver disease?
    Šmíd V
    Cas Lek Cesk; 2021; 160(2-3):65-70. PubMed ID: 34134495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonalcoholic Steatohepatitis: A Review.
    Sheka AC; Adeyi O; Thompson J; Hameed B; Crawford PA; Ikramuddin S
    JAMA; 2020 Mar; 323(12):1175-1183. PubMed ID: 32207804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-alcoholic fatty liver disease in obese adults: clinical aspects and current management strategies.
    Pallayova M; Taheri S
    Clin Obes; 2014 Oct; 4(5):243-53. PubMed ID: 25825857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe.
    Lazarus JV; Ekstedt M; Marchesini G; Mullen J; Novak K; Pericàs JM; Roel E; Romero-Gómez M; Ratziu V; Tacke F; Cortez-Pinto H; Anstee QM;
    J Hepatol; 2020 Jan; 72(1):14-24. PubMed ID: 31518646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review article: shared disease mechanisms between non-alcoholic fatty liver disease and metabolic syndrome - translating knowledge from systems biology to the bedside.
    Sookoian S; Pirola CJ
    Aliment Pharmacol Ther; 2019 Mar; 49(5):516-527. PubMed ID: 30714632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of NAFLD and Its Management.
    Mundi MS; Velapati S; Patel J; Kellogg TA; Abu Dayyeh BK; Hurt RT
    Nutr Clin Pract; 2020 Feb; 35(1):72-84. PubMed ID: 31840865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-alcoholic fatty liver disease and lifestyle modifications, focusing on physical activity.
    Kwak MS; Kim D
    Korean J Intern Med; 2018 Jan; 33(1):64-74. PubMed ID: 29202557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of diet and lifestyle changes in nonalcoholic fatty liver disease.
    Nseir W; Hellou E; Assy N
    World J Gastroenterol; 2014 Jul; 20(28):9338-44. PubMed ID: 25071328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of a structured lifestyle programme on patients with metabolic syndrome complicated by non-alcoholic fatty liver disease.
    Konerman MA; Walden P; Joseph M; Jackson EA; Lok AS; Rubenfire M
    Aliment Pharmacol Ther; 2019 Feb; 49(3):296-307. PubMed ID: 30561027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Future of Nonalcoholic Fatty Liver Disease Treatment.
    Mazhar K
    Med Clin North Am; 2019 Jan; 103(1):57-69. PubMed ID: 30466676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design.
    Xu ZJ; Shi JP; Yu DR; Zhu LJ; Jia JD; Fan JG
    Adv Ther; 2016 Nov; 33(11):2069-2081. PubMed ID: 27743352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis.
    Ratziu V; Ghabril M; Romero-Gomez M; Svegliati-Baroni G
    Transplantation; 2019 Jan; 103(1):28-38. PubMed ID: 30300289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonalcoholic steatohepatitis diagnosis and treatment from the perspective of patients and primary care physicians: a cross-sectional survey.
    Nadolsky K; Cryer DR; Articolo A; Fisher T; Schneider J; Rinella M
    Ann Med; 2023 Dec; 55(1):2211349. PubMed ID: 37171239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Managing non-alcoholic fatty liver disease.
    Ngu JH; Goh GB; Poh Z; Soetikno R
    Singapore Med J; 2016 Jul; 57(7):368-71. PubMed ID: 27439352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.